Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer

  • Dopeso, Higinio|||0000-0003-0060-1861
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Bazzocco, Sarah
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Macaya, Irati|||0000-0001-5698-6452
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Anguita, Estefanía|||0000-0003-2230-7030
  • Masanas, Marc|||0000-0002-2249-8554
  • Jiménez-Flores, Lizbeth M.
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Segura, Miguel F.|||0000-0003-0916-3618
  • Schwartz, Simon|||0000-0001-8297-7971
  • Mariadason, John M.|||0000-0001-9123-7684
  • Arango, Diego|||0000-0003-2953-3284
Reduced RHOA signalling has been shown to increase the growth/metastatic potential of colorectal tumours. However, the mechanisms of inactivation of RHOA signalling in colon cancer have not been characterised. A panel of colorectal cancer cell lines and large cohorts of primary tumours were used to investigate the expression and activity of RHOA, as well as the presence of RHOA mutations/deletions and promoter methylation affecting RHOA. Changes in RHOA expression were assessed by western blotting and qPCR after modulation of microRNAs, SMAD4 and c-MYC. We show here that RHOA point mutations and promoter hypermethylation do not significantly contribute to the large variability of RHOA expression observed among colorectal tumours. However, RHOA copy number loss was observed in 16% of colorectal tumours and this was associated with reduced RHOA expression. Moreover, we show that miR-200a/b/429 downregulates RHOA in colorectal cancer cells. In addition, we found that TGF- β /SMAD4 upregulates the RHOA promoter. Conversely, RHOA expression is transcriptionally downregulated by canonical Wnt signalling through the Wnt target gene c-MYC that interferes with the binding of SP1 to the RHOA promoter in colon cancer cells. We demonstrate a complex pattern of inactivation of the tumour suppressor gene RHOA in colon cancer cells through genetic, transcriptional and post-transcriptional mechanisms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Tumor expression of cyclin-dependent kinase 5 (Cdk5) is a prognostic biomarker and predicts outcome of oxaliplatin-treated metastatic colorectal cancer patients

  • Ruiz de Porras, Vicenç|||0000-0002-4352-1784
  • Bystrup, Sara|||0000-0002-7971-0851
  • Cabrero de las Heras, Sara
  • Musulén, Eva|||0000-0002-9667-6464
  • Palomero, Luis|||0000-0002-9144-1017
  • Alonso, María Henar
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Arango, Diego|||0000-0003-2953-3284
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Queralt, C.|||0000-0001-9875-0173
  • Manzano Mozo, José Luís
  • Layos, Laura
  • Bugés, Cristina|||0000-0003-2013-1510
  • Martínez Balibrea, Eva|||0000-0002-4501-7100
In recent years, an increasing number of studies have shown that elevated expression of cyclin dependent kinase (Cdk5) contributes to the oncogenic initiation and progression of many types of cancers. In this study, we investigated the expression pattern of Cdk5 in colorectal cancer (CRC) cell lines and in a large number of tumor samples in order to evaluate its relevance in this pathogenesis and possible use as a prognostic marker. We found that Cdk5 is highly expressed and activated in CRC cell lines and that silencing of the kinase decreases their migration ability. In tumor tissues, Cdk5 is overexpressed compared to normal tissues due to a copy number gain. In patients with localized disease, we found that high Cdk5 levels correlate with poor prognosis, while in the metastatic setting, this was only the case for patients receiving an oxaliplatin-based treatment. When exploring the Cdk5 levels in the consensus molecular subtypes (CMS), we found the lowest levels in subtype 1, where high Cdk5 again was associated with a poorer prognosis. In conclusion, we confirm that Cdk5 is involved in CRC and disease progression and that it could serve as a prognostic and predictive biomarker in this disease.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

PVT1 Long Non-coding RNA in Gastrointestinal Cancer

  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Arango, Diego|||0000-0003-2953-3284
  • Dopeso, Higinio|||0000-0003-0060-1861
Whole genome and transcriptome sequencing technologies have led to the identification of many long non-coding RNAs (lncRNAs) and stimulated the research of their role in health and disease. LncRNAs participate in the regulation of critical signaling pathways including cell growth, motility, apoptosis, and differentiation; and their expression has been found dysregulated in human tumors. Thus, lncRNAs have emerged as new players in the initiation, maintenance and progression of tumorigenesis. PVT1 (plasmacytoma variant translocation 1) lncRNA is located on chromosomal 8q24.21, a large locus frequently amplified in human cancers and predictive of increased cancer risk in genome-wide association studies (GWAS). Combined, colorectal and gastric adenocarcinomas are the most frequent tumor malignancies and also the leading cause of cancer-related deaths worldwide. PVT1 expression is elevated in gastrointestinal tumors and correlates with poor patient prognosis. In this review, we discuss the mechanisms of action underlying PVT1 oncogenic role in colorectal and gastric cancer such as MYC upregulation, miRNA production, competitive endogenous RNA (ceRNA) function, protein stabilization, and epigenetic regulation. We also illustrate the potential role of PVT1 as prognostic biomarker and its relationship with resistance to current chemotherapeutic treatments.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Loss of the EPH receptor B6 contributes to colorectal cancer metastasis

  • Mateo-Lozano, Silvia
  • Bazzocco, Sarah
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • Mazzolini, Rocco|||0000-0003-3249-8387
  • Andretta, Elena
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Fernández Caparrós, Yolanda
  • del Llano, Edgar
  • Bilic Zimmermann, Josipa|||0000-0001-9642-6265
  • Suárez-López, Lucía
  • Macaya, Irati|||0000-0001-5698-6452
  • Cartón-Garcia, Fernando|||0000-0002-1858-6551
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Jimenez-Flores, Lizbeth M.
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Núñez, Yáiza|||0000-0001-7268-2125
  • Afonso, Elsa
  • Cacci, Karina
  • Hernandez-Losa, Javier|||0000-0003-1526-3201
  • Landolfi, Stefania|||0000-0002-1059-635X
  • Abasolo, Ibane|||0000-0001-5970-6276
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Mariadason, John M.|||0000-0001-9123-7684
  • Schwartz, Simon|||0000-0001-8297-7971
  • Matsui, Toshimitsu
  • Arango, Diego|||0000-0003-2953-3284
Although deregulation of EPHB signaling has been shown to be an important step in colorectal tumorigenesis, the role of EPHB6 in this process has not been investigated. We found here that manipulation of EPHB6 levels in colon cancer cell lines has no effect on their motility and growth on a solid substrate, soft agar or in a xenograft mouse model. We then used an EphB6 knockout mouse model to show that EphB6 inactivation does not efficiently initiate tumorigenesis in the intestinal tract. In addition, when intestinal tumors are initiated genetically or pharmacologically in EphB6 +/+ and EphB6 -/- mice, no differences were observed in animal survival, tumor multiplicity, size or histology, and proliferation of intestinal epithelial cells or tumor cells. However, reintroduction of EPHB6 into colon cancer cells significantly reduced the number of lung metastasis after tail-vein injection in immunodeficient mice, while EPHB6 knockdown in EPHB6-expressing cells increased their metastatic spread. Consistently, although EPHB6 protein expression in a series of 130 primary colorectal tumors was not associated with patient survival, EPHB6 expression was significantly lower in lymph node metastases compared to primary tumors. Our results indicate that the loss of EPHB6 contributes to the metastatic process of colorectal cancer.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis

  • Bazzocco, Sarah
  • Dopeso, Higinio|||0000-0003-0060-1861
  • Martínez-Barriocanal, Águeda|||0000-0002-8809-160X
  • Anguita, Estefanía|||0000-0003-2230-7030
  • Nieto Raya, Rocio|||0000-0001-8567-2268
  • Li, Jing|||0000-0002-9283-3821
  • Garcia-Vidal, Elia|||0000-0002-2756-9438
  • Maggio, Valentina|||0000-0002-4985-5611
  • Rodrigues, Paulo|||0000-0002-5380-2715
  • de Marcondes, Priscila Guimarães|||0000-0001-7271-2881
  • Schwartz, Simon|||0000-0001-8297-7971
  • Aaltonen, Lauri A.|||0000-0001-6839-4286
  • Sánchez, Alex|||0000-0002-8673-7737
  • Mariadason, John M.|||0000-0001-9123-7684
  • Arango, Diego|||0000-0003-2953-3284
Cancer initiation and progression are driven by genetic and epigenetic changes. Although genome/exome sequencing has significantly contributed to the characterization of the genetic driver alterations, further investigation is required to systematically identify cancer driver genes regulated by promoter hypermethylation. Using genome-wide analysis of promoter methylation in 45 colorectal cancer cell lines, we found that higher overall methylation levels were associated with microsatellite instability (MSI), faster proliferation and absence of APC mutations. Because epigenetically silenced genes could represent important oncogenic drivers, we used mRNA expression profiling of colorectal cancer cell lines and primary tumors to identify a subset of 382 (3.9%) genes for which promoter methylation was negatively associated with gene expression. Remarkably, a significant enrichment in zinc finger proteins was observed, including the transcriptional repressor ZBTB18. Re-introduction of ZBTB18 in colon cancer cells significantly reduced proliferation in vitro and in a subcutaneous xenograft mouse model. Moreover, immunohistochemical analysis revealed that ZBTB18 is frequently lost or reduced in colorectal tumors, and reduced ZBTB18 expression was found to be associated with lymph node metastasis and shorter survival of patients with locally advanced colorectal cancer. We identified a set of 382 genes putatively silenced by promoter methylation in colorectal cancer that could significantly contribute to the oncogenic process. Moreover, as a proof of concept, we demonstrate that the epigenetically silenced gene ZBTB18 has tumor suppressor activity and is a novel prognostic marker for patients with locally advanced colorectal cancer. The online version contains supplementary material available at 10.1186/s13148-021-01070-0.